## Filippo Canducci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5094632/publications.pdf

Version: 2024-02-01

218592 206029 2,482 53 26 citations h-index papers

g-index 53 53 53 4374 docs citations times ranked citing authors all docs

48

#	Article	IF	CITATIONS
1	High frequency of intestinal T <sub>H</sub> 17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Science Advances, 2017, 3, e1700492.	4.7	228
2	The Microbiome of the Prostate Tumor Microenvironment. European Urology, 2017, 72, 625-631.	0.9	154
3	Twoâ€year prospective study of single infections and coâ€infections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease. Journal of Medical Virology, 2008, 80, 716-723.	2.5	144
4	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nature Communications, 2018, 9, 4832.	5.8	144
5	Loss of gut barrier integrity triggers activation of islet-reactive T cells and autoimmune diabetes.  Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15140-15149.	3.3	134
6	<i>Coronaviridae</i> and SARS-associated Coronavirus Strain HSR1. Emerging Infectious Diseases, 2004, 10, 413-418.	2.0	127
7	Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by Modulating Microbiota and Promoting Indoleamine 2,3-Dioxygenase-Enriched Tolerogenic Intestinal Environment. Journal of Diabetes Research, 2016, 2016, 1-12.	1.0	111
8	Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Clinical Strains Isolated in Italy. Journal of Clinical Microbiology, 2006, 44, 2485-2491.	1.8	98
9	The role of infections and coinfections with newly identified and emerging respiratory viruses in children. Virology Journal, 2012, 9, 247.	1.4	97
10	Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir. Journal of Infectious Diseases, 2011, 204, 1811-1815.	1.9	94
11	Persistent Symptomless Human Metapneumovirus Infection in Hematopoietic Stem Cell Transplant Recipients. Journal of Infectious Diseases, 2006, 194, 474-478.	1.9	89
12	The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nature Reviews Urology, 2016, 13, 77-90.	1.9	89
13	Testicular microbiome in azoospermic menâ€"first evidence of the impact of an altered microenvironment. Human Reproduction, 2018, 33, 1212-1217.	0.4	83
14	Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. Aids, 2009, 23, 455-460.	1.0	66
15	Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. Journal of Antimicrobial Chemotherapy, 2010, 65, 425-433.	1.3	53
16	Persistent Replication of Severe Acute Respiratory Syndrome Coronavirus in Human Tubular Kidney Cells Selects for Adaptive Mutations in the Membrane Protein. Journal of Virology, 2008, 82, 5137-5144.	1.5	50
17	Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. Aids, 2010, 24, 924-928.	1.0	43
18	Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology, 2010, 399, 144-152.	1.1	40

#	Article	IF	Citations
19	Kuwanonâ€L as a New Allosteric HIVâ€1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation. ChemBioChem, 2015, 16, 2507-2512.	1.3	39
20	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiologica, 2010, 33, 195-206.	0.1	35
21	Prenylated phloroglucinols from Hypericum scruglii, an endemic species of Sardinia (Italy), as new dual HIV-1 inhibitors effective on HIV-1 replication. PLoS ONE, 2018, 13, e0195168.	1.1	34
22	Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients. Journal of Medical Virology, 2010, 82, 153-156.	2.5	30
23	Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. Virology, 2004, 327, 242-248.	1.1	28
24	Adaptive immunity against gut microbiota enhances apoE-mediated immune regulation and reduces atherosclerosis and western-diet-related inflammation. Scientific Reports, 2016, 6, 29353.	1.6	28
25	Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach. Scientific Reports, 2017, 7, 5013.	1.6	28
26	Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic Plaques. Journal of Immunology, 2009, 183, 2537-2544.	0.4	27
27	In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. Journal of Antimicrobial Chemotherapy, 2013, 68, 2525-2532.	1.3	27
28	Natural Product Kuwanonâ€L Inhibits HIVâ€1 Replication through Multiple Target Binding. ChemBioChem, 2017, 18, 374-377.	1.3	27
29	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. Journal of Antimicrobial Chemotherapy, 2012, 67, 213-217.	1.3	26
30	Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides. PLoS ONE, 2018, 13, e0198478.	1.1	25
31	Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the <i>N</i> -Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family. Journal of Medicinal Chemistry, 2016, 59, 2747-2759.	2.9	22
32	Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). New Microbiologica, 2009, 32, 319-24.	0.1	22
33	<i>Helicobacter pylori</i> Treatment: A Role for Probiotics?. Digestive Diseases, 2001, 19, 144-147.	0.8	21
34	Anti-HIV-1 Response Elicited in Rabbits by Anti-Idiotype Monoclonal Antibodies Mimicking the CD4-Binding Site. PLoS ONE, 2008, 3, e3423.	1.1	21
35	Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. Retrovirology, 2009, 6, 4.	0.9	18
36	Cross-Reacting Antibacterial Auto-Antibodies Are Produced within Coronary Atherosclerotic Plaques of Acute Coronary Syndrome Patients. PLoS ONE, 2012, 7, e42283.	1.1	17

#	Article	IF	Citations
37	Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. New Microbiologica, 2007, 30, 255-8.	0.1	17
38	Evolutionary Characteristics of HIV Type 1 Variants Resistant to Protease Inhibitors in the Absence of Drug-Selective Pressure. AIDS Research and Human Retroviruses, 2003, 19, 1151-1153.	0.5	16
39	Inhibition of HIVâ€1 Reverse Transcriptase Dimerization by Small Molecules. ChemBioChem, 2016, 17, 683-688.	1.3	15
40	Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e51-e53.	0.9	14
41	Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. Journal of Antimicrobial Chemotherapy, 2012, 67, 1224-1227.	1.3	14
42	Pregnancy and H1N1 infection. Lancet, The, 2009, 374, 1417.	6.3	13
43	2-Aminothiazolones as Anti-HIV Agents That Act as gp120-CD4 Inhibitors. Antimicrobial Agents and Chemotherapy, 2014, 58, 3043-3052.	1.4	13
44	Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1391-1395.	1.3	10
45	The new and less toxic protease inhibitor saquinavir–NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. Antiviral Research, 2011, 91, 292-295.	1.9	9
46	Increased iNKT17 Cell Frequency in the Intestine of Non-Obese Diabetic Mice Correlates With High Bacterioidales and Low Clostridiales Abundance. Frontiers in Immunology, 2018, 9, 1752.	2.2	8
47	One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2502-2505.	1.0	8
48	Epidemiological, molecular and clinical features of Enterovirus 109 infection in children and in adult stem cell transplant recipients. Virology Journal, 2012, 9, 183.	1.4	6
49	Quantitation of Bacillus clausii in biological samples by real-time polymerase chain reaction. Journal of Microbiological Methods, 2006, 65, 632-636.	0.7	5
50	Cloning and molecular characterization of a human recombinant $\log F$ ab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient. Molecular Immunology, 2006, 43, 1363-1369.	1.0	4
51	Infection and Coinfection of Human Rhinovirus C in Stem Cell Transplant Recipients. Clinical and Developmental Immunology, 2013, 2013, 1-5.	3.3	4
52	IL28B rs12979860 genotype as a predictor marker of progression to BKVirus Associated nephropathy, after kidney transplantation. Scientific Reports, 2017, 7, 6746.	1.6	4
53	Immunological Recovery After 24 Weeks of Antiretroviral Therapy in Patients With X4 Virus During Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e27-e29.	0.9	3